Luteolin Mitigates Diabetic Dyslipidemia in Rats by Modulating ACAT-2, PPARα, SREBP-2 Proteins, and Oxidative Stress

Syed Ilyas Shehnaz1, Anitha Roy2, Rajagopalan Vijayaraghavan3

  • 1Department of Pharmacology, Saveetha Medical College & Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, 602105, Tamil Nadu, India. shehnazilyas@yahoo.com.

Insights

Luteolin, a natural flavonoid, effectively improved lipid profiles and reduced liver damage in diabetic rats. This suggests luteolin

Area of Science:

  • Biochemistry
  • Pharmacology
  • Endocrinology

Background:

  • Diabetic dyslipidemia links type-2 diabetes mellitus (T2DM) to cardiovascular disease.
  • Natural compounds like luteolin show potential for managing T2DM and related complications.
  • Luteolin possesses antioxidant, hypolipidemic, and antiatherogenic properties.

Purpose of the Study:

  • To investigate the effects of luteolin on lipid homeostasis and liver damage in a rat model of T2DM.
  • To elucidate the underlying mechanisms of luteolin's action in diabetic dyslipidemia.

Main Methods:

  • Type-2 diabetes mellitus was induced in Wistar rats using a high-fat diet (HFD) and streptozotocin (STZ).
  • Diabetic rats were treated with varying doses of luteolin, atorvastatin, or a control.
  • Lipid profiles, atherogenic index, oxidative stress markers, and hepatic function were assessed.
  • Expression levels of key proteins (PPARα, ACAT-2, SREBP-2) were analyzed.

Main Results:

  • Luteolin significantly improved lipid profiles and reduced the atherogenic index in a dose-dependent manner.
  • Luteolin ameliorated oxidative stress by regulating malondialdehyde, superoxide dismutase, catalase, and glutathione levels.
  • Luteolin modulated PPARα expression and downregulated ACAT-2 and SREBP-2, alleviating hepatic impairment.

Conclusions:

  • Luteolin demonstrates efficacy in managing diabetic dyslipidemia and associated hepatic damage in T2DM rats.
  • Mechanisms include amelioration of oxidative stress and modulation of lipid metabolism-related protein expression.
  • Further research is warranted to confirm luteolin's therapeutic potential for T2DM patients.